위고비, 살만 빠지는 게 아니었다?! – 동아사이언스
Semaglutide, the active ingredient in the weight-loss medication Wegovy, is demonstrating significant potential in treating metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of liver disease. While originally developed for chronic weight management and type 2 diabetes, clinical data indicates that the drug’s mechanism—mimicking the glucagon-like peptide-1 (GLP-1) hormone—may address the underlying liver inflammation and fibrosis … Read more
